0
0
On October 20, 2025, Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) had approved its novel eye therapy, Epioxa, providing an innovative and less invasive treatment option for keratoconus patients. This marked the first FDA-cleared topical drug therapy for keratoconus that does not require removal of the corneal epithelium—the eye’s outer protective layer—offering patients significantly improved comfort and quicker recovery.
Keratoconus and Need for New Treatments
Keratoconus is a progressive eye disorder characterized by thinning and weakening of the cornea, which leads to distorted vision and increased risk of vision loss. It often presents in people under 30 and remains widely underdiagnosed and undertreated. Traditional treatment approaches, such as eyeglasses and contact lenses, address visual symptoms but do not halt the progression. Corneal cross-linking procedures, involving removal of the epithelium and UV light activation to strengthen corneal tissue, have been effective in slowing disease progression but are associated with pain, longer healing times, and potential complications.
Epioxa’s Innovative Therapeutic Approach
Epioxa represents a major advance as an incision-free, topical corneal cross-linking therapy using two oxygen-enriched bioactive formulations, Epioxa HD and Epioxa, applied sequentially and activated by ultraviolet light in an oxygen-enhanced environment. This approach preserves the corneal epithelium, eliminating the painful and invasive step of epithelial removal common in current treatments. The therapy is designed to improve patient comfort, reduce recovery time, and maintain strong clinical efficacy.
Clinical Evidence and FDA Approval
The FDA approval was supported by robust data from two phase 3 randomized, multicenter, double-masked clinical trials involving over 400 patients with keratoconus. Both trials met their primary efficacy endpoints by demonstrating significant improvement in corneal stability at 12 months, with favorable safety and tolerability profiles. This strong evidence base underpins Epioxa’s potential to become a new standard of care.
Expert Perspectives
Thomas Burns, Chairman and CEO of Glaukos, highlighted the significance of this approval, stating it “ushers in a new standard-of-care for patients suffering from keratoconus with the first FDA-approved topical drug therapy that does not require removal of the corneal epithelium.” He emphasized the therapy’s impact on improving patient comfort and minimizing recovery time as a “game-changing new treatment”.
Corneal specialist Dr. W. Barry Lee, President of the Cornea Society, noted that the pain and healing time associated with existing cross-linking therapies have been major barriers to care. He commended Epioxa as an incision-free, epithelium-preserving treatment that addresses these challenges, thereby potentially expanding patient access and improving quality of life.
Implications for Public Health and Patient Access
Keratoconus affects thousands but is often underdiagnosed. With the approval of Epioxa, Glaukos plans to launch awareness campaigns focusing on earlier diagnosis and improving access. Key initiatives include patient co-payment assistance, support for treatment pathways, education for healthcare providers, and promotion of screening programs. Early intervention is crucial to prevent disease progression and reduce the need for corneal transplantation, a procedure sometimes necessary in advanced cases.
Potential Limitations and Considerations
While Epioxa presents a less invasive option with promising outcomes, it remains essential to monitor long-term effectiveness and safety beyond the 12-month trial period. Costs, insurance coverage, and real-world accessibility will also influence uptake. Additionally, as with all novel therapies, patient selection criteria and adherence to treatment protocols will be critical to achieving optimal results.
Conclusion
The FDA’s approval of Epioxa marks a pivotal advancement in keratoconus care, shifting treatment paradigms toward a more patient-friendly, non-incisional approach. By preserving the corneal epithelium, Epioxa reduces pain and recovery times, while effectively stabilizing the cornea. This innovation promises to increase treatment adoption, improve patient outcomes, and reduce the burden of this progressive disease.
Glaukos expects Epioxa to be commercially available by the first quarter of 2026, backed by ongoing efforts to raise awareness, improve diagnosis rates, and facilitate access to this groundbreaking therapy.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
